# Cytochrome P450 3A
**Cytochrome P450 3A (CYP3A)** is a subfamily of human cytochrome P450 enzymes, hemoprotein monooxygenases that catalyze the oxidative metabolism of a large share of all drugs, making it the most important enzyme system in drug clearance and drug-drug interactions. Members of the family collectively metabolize more than half of all currently prescribed medications, with estimates ranging from about 50% of marketed drugs to about 60% of currently known drugs.[1](https://pubmed.ncbi.nlm.nih.gov/15762770/) • [2](https://pubmed.ncbi.nlm.nih.gov/18058330/) • [3](https://pubmed.ncbi.nlm.nih.gov/32789028/)
| Key fact | Detail |
|---|---|
| Drug burden | CYP3A metabolizes about 60% of currently known drugs; CYP3A4 alone mediates roughly half of all marketed drugs[1](https://pubmed.ncbi.nlm.nih.gov/15762770/) • [2](https://pubmed.ncbi.nlm.nih.gov/18058330/) |
| Human isoforms | At least CYP3A4, CYP3A5, and CYP3A7; CYP3A7 is expressed only in fetal liver and CYP3A43 is of uncertain significance[4](https://pubmed.ncbi.nlm.nih.gov/10628899/) • [5](https://cpicpgx.org/content/guideline/publication/tacrolimus/2015/25801146.pdf) |
| Hepatic abundance | CYP3A4 is the most highly expressed P450 in the liver, comprising up to 40% of hepatic P450 content[6](https://pmc.ncbi.nlm.nih.gov/articles/PMC2987628/) |
| Clinical index substrates | Midazolam and triazolam[7](https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers) |
| Strong index inhibitors | Clarithromycin and itraconazole; moderate index inhibitors include erythromycin, fluconazole, and verapamil[7](https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers) |
| Strong index inducers | Carbamazepine, phenytoin, and rifampin[7](https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers) |
| Pharmacogenetics | CYP3A5 genotype guides tacrolimus dosing; *1 carriers require 1.5 to 2 times the standard dose[8](https://pmc.ncbi.nlm.nih.gov/articles/PMC4481158/) |
## Isoforms and expression
The CYP3A subfamily is the most abundant group of CYP enzymes in the liver and consists of at least three isoforms, CYP3A4, CYP3A5, and CYP3A7.[4](https://pubmed.ncbi.nlm.nih.gov/10628899/) Four genes in the family have been described, but only CYP3A4 and CYP3A5 are thought to be relevant in adults; CYP3A7 is expressed only in fetal liver, and CYP3A43 is of uncertain significance.[5](https://cpicpgx.org/content/guideline/publication/tacrolimus/2015/25801146.pdf)
**CYP3A4 dominates adult drug metabolism.** It is the most highly expressed P450 in the liver, comprising up to 40% of hepatic P450 content, and is also the most promiscuous P450, contributing to the metabolism of approximately 50% of all pharmaceuticals on the market, including cyclosporin, bromocriptine, macrolide antibiotics, and statins.[6](https://pmc.ncbi.nlm.nih.gov/articles/PMC2987628/) Because of its abundant expression in both the liver and small intestine, CYP3A4 contributes significantly to first-pass and systemic metabolism, making it an important determinant of oral bioavailability and systemic drug exposure.[9](https://pmc.ncbi.nlm.nih.gov/articles/PMC10565868/)
**CYP3A5 is genetically variable.** CYP3A4 and CYP3A5 have 83% amino acid sequence similarity and overlapping substrate specificity, for example in the metabolism of steroid hormones, nifedipine, cyclosporine, and fentanyl.[10](https://pmc.ncbi.nlm.nih.gov/articles/PMC9399309/) The CYP3A5*3 allele, a variant in intron 3 (rs776746) that creates a cryptic splice site and degrades the transcript, explains the highly variable hepatic expression of the enzyme. Based on homozygosity for this allele, individuals are classified as CYP3A5 non-expressers (*3/*3) or expressers (*1/*3 and *1/*1). CYP3A5 is expressed in only 10 to 30% of Europeans and Asians but in approximately 70% of people of African ancestry, because the *3, *6, and *7 nonfunctional alleles differ in frequency across populations.[10](https://pmc.ncbi.nlm.nih.gov/articles/PMC9399309/)
## Substrate breadth and atypical kinetics
The defining biochemical feature of CYP3A is its unusually low substrate specificity, which allows it to bind a large and structurally diverse set of compounds.[1](https://pubmed.ncbi.nlm.nih.gov/15762770/) • [3](https://pubmed.ncbi.nlm.nih.gov/32789028/) This breadth has a cost: it also makes CYP3A4 susceptible to reversible or irreversible inhibition by a variety of drugs.[1](https://pubmed.ncbi.nlm.nih.gov/15762770/)
CYP3A4 provides striking examples of non-Michaelis-Menten kinetics, including homotropic cooperativity, and is known to bind and metabolize multiple substrates simultaneously; effectors may act at a noncatalytic site within the binding pocket to modulate substrate oxidation.[6](https://pmc.ncbi.nlm.nih.gov/articles/PMC2987628/) Structural work indicates that the malleability of the F-F' loop (residues 211 to 218) defines the broad substrate specificity of CYP3A4, and that the metyrapone-bound complex is stabilized both by direct coordination to the heme iron and by a hydrogen bond between the metyrapone carbonyl oxygen and the Ser119 hydroxyl.[11](https://pmc.ncbi.nlm.nih.gov/articles/PMC3787833/)
## Inhibition and drug-drug interactions
**Mechanism-based inhibition** occurs when a drug is converted by CYP enzymes to a reactive metabolite that irreversibly binds covalently to CYP3A4. It is characterized by NADPH-, time-, and concentration-dependent enzyme inactivation, and because the inactivated enzyme must be replaced by newly synthesized CYP3A4 protein, it more frequently causes pharmacokinetic drug-drug interactions than reversible inhibition. The apparent effect of such an inhibitor is a function of its K(I), k(inact), and partition ratio, together with the zero-order synthesis rate of replacement enzyme.[1](https://pubmed.ncbi.nlm.nih.gov/15762770/)
Clinically important mechanism-based CYP3A4 inhibitors span several drug classes: antibacterials (clarithromycin, erythromycin, isoniazid), anticancer agents (tamoxifen, irinotecan), anti-HIV agents (ritonavir, [delavirdine](https://www.edgepedia.org/delavirdine)), antihypertensives ([dihydralazine](https://www.edgepedia.org/dihydralazine), verapamil, diltiazem), sex steroids and their receptor modulators (gestodene, raloxifene), and herbal constituents such as bergamottin and glabridin. Drugs that inactivate CYP3A4 often share moieties such as a tertiary amine function, a furan ring, or an acetylene function.[1](https://pubmed.ncbi.nlm.nih.gov/15762770/) Several theories, not necessarily mutually exclusive, exist about the primary mechanism by which ritonavir inactivates CYP3A4.[12](https://pmc.ncbi.nlm.nih.gov/articles/PMC9456214/)
The consequences can be severe. If terfenadine, [cisapride](https://www.edgepedia.org/cisapride), or astemizole, each a CYP3A4 substrate, is given alongside a drug that inhibits CYP3A4, the result can be torsades de pointes, a QT-prolonging ventricular arrhythmia that threatens life.[1](https://pubmed.ncbi.nlm.nih.gov/15762770/) CYP3A4 is also the primary enzyme involved in food-drug interactions.[6](https://pmc.ncbi.nlm.nih.gov/articles/PMC2987628/)
**Induction works in the opposite direction.** Strong clinical index inducers of CYP3A, carbamazepine, phenytoin, and rifampin, decrease the AUC (area under the drug concentration-time curve, measuring total drug exposure) of sensitive substrates by at least 80 percent, potentially reducing therapeutic effect; coadministration of [elvitegravir](https://www.edgepedia.org/elvitegravir) with CYP3A inducers, for example, may decrease its plasma concentration.[7](https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers) • [13](https://www.fda.gov/drugs/guidances-drugs/guidance-recap-podcast-clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter)
## Interaction with P-glycoprotein
P-glycoprotein (P-gp), an efflux transporter, and CYP3A are frequently co-expressed in the same cells and share a large number of substrates and modulators, so the disposition of such drugs is affected by both metabolism and transport.[2](https://pubmed.ncbi.nlm.nih.gov/18058330/) Many CYP3A inhibitors are also P-gp inhibitors; the FDA's index inhibitor table flags clarithromycin, itraconazole, erythromycin, verapamil, and ketoconazole as P-gp inhibitors, defined as those increasing the AUC of digoxin to at least 1.25-fold.[7](https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers) This overlap confounds in vitro-in vivo extrapolation, since CYP3A4 inactivators can themselves be inducers and P-gp substrates or inhibitors.[1](https://pubmed.ncbi.nlm.nih.gov/15762770/)
## Pharmacogenetics and tacrolimus
The most robust clinical application of CYP3A genetics concerns tacrolimus, the first-line immunosuppressant used to prevent graft rejection in solid organ transplantation. Tacrolimus is metabolized in the gut and liver primarily by CYP3A4 and CYP3A5, with CYP3A5's contribution varying by genotype; POR supplies electrons from NADPH to microsomal P450 enzymes rather than directly metabolizing tacrolimus. Because tacrolimus has a narrow therapeutic index, monitoring of drug levels during treatment is standard practice.[10](https://pmc.ncbi.nlm.nih.gov/articles/PMC9399309/) • [8](https://pmc.ncbi.nlm.nih.gov/articles/PMC4481158/) • [17](https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0a557ca9-b1a1-cf8f-a317-e4d8d4d6e60f&type=display) Over 50 studies in kidney, heart, and lung transplant patients found that individuals with the CYP3A5*1/*1 or *1/*3 genotype have significantly lower dose-adjusted trough concentrations than *3/*3 individuals, with *1 carriers requiring 1.5 to 2 times the dose to achieve similar blood concentrations; CYP3A5*1/*3 is believed to explain up to 45% of the variability in tacrolimus dose.[8](https://pmc.ncbi.nlm.nih.gov/articles/PMC4481158/) A randomized controlled trial showed that genotype-based dosing reduced the time required to reach optimal drug exposure.[10](https://pmc.ncbi.nlm.nih.gov/articles/PMC9399309/) CPIC recommends individualizing initial tacrolimus dosing using CYP3A5 genotype when it is known, while noting that genotype-based dosing has not been shown to improve efficacy or reduce toxicity.[8](https://pmc.ncbi.nlm.nih.gov/articles/PMC4481158/)
For CYP3A4 itself, genetic variants were long thought to have a limited contribution to activity variability because of the unimodal distribution of enzyme activity and the wide range of hepatic protein expression; substantial interindividual variability instead arises from genetic variability, environmental factors, disease state, and comedications such as inducers and inhibitors.[9](https://pmc.ncbi.nlm.nih.gov/articles/PMC10565868/)
## Study methods and regulatory use
Human liver microsomes serve as the conventional in vitro tool for determining the kinetic parameters of CYP3A4 inactivation, namely the concentration giving half-maximal inactivation (K(I)) and the maximal inactivation rate reached at saturation (k(inact)); the study of CYP3A4 inactivation draws on in vitro, in silico, and in vivo models alike.[1](https://pubmed.ncbi.nlm.nih.gov/15762770/) The FDA recommends using two structurally unrelated CYP3A4/5 substrates, with marker reactions of midazolam 1'-hydroxylation and testosterone 6β-hydroxylation, to evaluate in vitro CYP3A4/5 inhibition.[7](https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers) [In vitro](https://www.edgepedia.org/in-vitro) results, together with clinical pharmacokinetic data, inform risk-based decisions about whether clinical drug-drug interaction studies are needed and how risk is communicated in labeling.[14](https://www.fda.gov/drugs/guidances-drugs/guidance-recap-podcast-in-vitro-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter) The ICH M12 guidance, issued in final form in August 2024, harmonizes regional recommendations for designing, conducting, and interpreting these evaluations.[15](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m12-drug-interaction-studies)
**Isoform-selective tools** have clarified individual roles. Members of the CYP3A family are commonly regarded as having enough overlapping substrate specificity to justify treating them as a single enzyme, and many studies annotate results as "CYP3A4/5". In 2012, two groups published the first reports of CYP3A4-selective inhibitors: SR-9186, a reversible inhibitor with 1000-fold selectivity over CYP3A5, and CYP3cide, a mechanism-based (irreversible) CYP3A4-selective inhibitor.[16](https://pmc.ncbi.nlm.nih.gov/articles/PMC7418881/)
## References
1. [Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs, PubMed](https://pubmed.ncbi.nlm.nih.gov/15762770/)
2. [Drugs as CYP3A probes, inducers, and inhibitors, PubMed](https://pubmed.ncbi.nlm.nih.gov/18058330/)
3. [Structural Perspectives of the CYP3A Family and Their Small Molecule Modulators in Drug Metabolism, PubMed](https://pubmed.ncbi.nlm.nih.gov/32789028/)
4. [Cytochrome P450 3A: ontogeny and drug disposition, PubMed](https://pubmed.ncbi.nlm.nih.gov/10628899/)
5. [CPIC Guidelines for CYP3A5 Genotype and Tacrolimus Dosing (PDF)](https://cpicpgx.org/content/guideline/publication/tacrolimus/2015/25801146.pdf)
6. [Structural Features of Cytochromes P450 and Ligands that Affect Drug Metabolism, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC2987628/)
7. [Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers, FDA](https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers)
8. [CPIC Guidelines for CYP3A5 Genotype and Tacrolimus Dosing, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC4481158/)
9. [CYP3A4 and CYP3A5 Genotyping Recommendations: Joint Consensus, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10565868/)
10. [PharmVar GeneFocus: CYP3A5, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC9399309/)
11. [Understanding the Mechanism of Cytochrome P450 3A4: Recent Advances and Remaining Problems, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3787833/)
12. [The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC9456214/)
13. [Guidance Recap Podcast: Clinical Drug Interaction Studies, FDA](https://www.fda.gov/drugs/guidances-drugs/guidance-recap-podcast-clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter)
14. [Guidance Recap Podcast: In Vitro Drug Interaction Studies, FDA](https://www.fda.gov/drugs/guidances-drugs/guidance-recap-podcast-in-vitro-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter)
15. [M12 Drug Interaction Studies, FDA](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m12-drug-interaction-studies)
16. [Structural Perspectives of the CYP3A Family, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC7418881/)
17. [These highlights do not include all the information needed to use TACROLIMUS CAPSULES safely and effectively. See full prescribing information for TACROLIMUS CAPSULES. TACROLIMUS capsules, for oral us](https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0a557ca9-b1a1-cf8f-a317-e4d8d4d6e60f&type=display)
---
*Topic: Encyclopedia › Life and health › Biological foundations › Biochemistry and metabolism › Enzyme classes and activities › Oxidoreductases, dehydrogenases, and cytochrome P450 › Cytochrome P450 enzymes and family members*
*Initially written Oct 21, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license